

ANNOUNCING THE SEVENTEENTH ROUND OF APPLICATIONS TO THE GLOBAL TB DRUG FACILITY CALL LIMITED TO PAEDIATRIC FORMULATED ANTI-TUBERCULOSIS DRUGS

The 17th round of applications to the Global Drug Facility (GDF) is now open and the GDF secretariat is accepting applications from governments for free grants of first-line **paediatric anti-tuberculosis drugs**. The closing date for receipt of applications is Monday, 15th October 2007. GDF grants for paediatric formulations have been made possible through funding from UNITAID (www.unitaid.eu).

The application materials are available on the GDF website:
http://www.stoptb.org/gdf/applying/application_documents.asp

Completed forms should be submitted to GDF (gdf@who.int) for consideration by its Technical Review Committee.

We encourage you to submit completed applications and supporting documents electronically. If an electronic submission is not possible, paper-based applications are accepted.

The following paediatric products are currently available from the Global Drug Facility:

1. Rifampicin 60mg/Isoniazid 30mg/ Pyrazinamide 150mg, Tablets, Dispersible (3-drug fixed dose combination) (RHZ 60/30/150)
2. Rifampicin 60mg/Isoniazid 60mg, Tablets, Dispersible (2-drug fixed dose combination) (RH 60/60)
3. Rifampicin 60mg/Isoniazid 30mg, Tablets, Dispersible (2-drug fixed dose combination) (RH 60/30)
4. Isoniazid 100mg Tablets, Breakable (H100)
5. Pyrazinamide 150mg Tablets, Breakable (Z150)

Please visit http://www.stoptb.org/gdf/drugsupply/drugs_available.asp for more details on these products.

Eligibility Criteria (as defined by UNITAID)¹

At least 85% of UNITAID funds should be spent on **low income countries (LICs)²** i.e. **with a GNI per capita < or equal to US\$ 875.**

No more than 10% of UNITAID funds should be spent on **lower middle income countries (LMICs)³** i.e. **with a GNI per capita ranging from US\$ 876 to \$3,465.**

No more than 5% of UNITAID funds should be spent on **upper middle income countries (UMICs)⁴** i.e. **with a GNI per capita ranging from US\$ 3,466 to \$10,725** with priority given to those with a high disease prevalence, subject to these countries providing co-financing for their projects as to 20% in year 1 rising to 40% in year 4 (the same arrangements as per the Global Fund).

¹ UNITAID Prospectus Sept. 2006

² As defined by the World Bank Atlas Method

³ Ibid

⁴ Ibid

In the case of both LMICS and UMICs, UNITAID contributions should be used to scale up existing programmes targeted principally at vulnerable groups (in accordance with the UNITAID definition).

The GDF Technical Review Committee (TRC) will consider all applications received from countries that are LICs, LMICs and UMICs taking into account the above criteria.

GDF grant support is dependent on approval by the GDF TRC and on the availability of resources.

Please send the application form to the following address:

**Global Drug Facility
Stop TB Partnership Secretariat
c/o World Health Organization
20, avenue Appia
CH-1211 Geneva 27
Switzerland
Fax: +41 22 791 4486 / +41 22 791 2111
Email: gdf@who.int**